Shilpa Medicare shines on launching Naturally Derived Option for Treatment of Oral Mucositis in India
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Shilpa Medicare is currently trading at Rs. 346.60, up by 9.05 points or 2.68% from its previous closing of Rs. 337.55 on the BSE.
The scrip opened at Rs. 344.95 and has touched a high and low of Rs. 357.70 and Rs. 342.80 respectively. So far 53001 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 384.70 on 31-Aug-2023 and a 52 week low of Rs. 222.40 on 28-Mar-2023.
Last one week high and low of the scrip stood at Rs. 357.70 and Rs. 332.00 respectively. The current market cap of the company is Rs. 3027.22 crore.
The promoters holding in the company stood at 50.01%, while Institutions and Non-Institutions held 9.01% and 40.99% respectively.
Shilpa Medicare has received approval from the Office of the Directorate of Ayurveda and Unani Services (division of the Ministry of Aayush) for the manufacture and sale of Oral Mucositis Spray a treatment option made available for the first time in India under the brand name ORAAL. The composition of ORAAL is protected by a granted patent in India until November 2033. Shilpa will commercialize the product under the brand name ORAAL which will be launched immediately. ORAAL, a substantial advancement in Oral Mucositis management, has been accepted and approved by the Indian Dental Association (IDA).
With the commitment towards ‘Thoughtful Innovation for Powerful Outcomes’, Shilpa’s ORAAL is indicated for the treatment of all grades of Mucositis. ORAAL is backed by required scientific proof for the treatment of Oral Mucositis. The launch of ORAAL, an Oral spray with a naturally derived formulation in India will offer great benefits in terms of flexibility and patient convenience for use in any condition, and is advantageous in reducing the chemical-based mouth rinse usage and also delivering appropriate dosing to the patient without any side effects. A dosage of 4-5 sprays, 2-3 times a day can maintain Oral hydration and work towards healing Oral Mucositis from the first spray itself and starts showing effects within 20 minutes.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
